출판:MarketsandMarkets
・Wearable Injectors Market by Product Type(On-Body and Off-Body), Therapy (Immuno-oncology, Diabetes, Cardiovascular diseases), Technology(Spring-based, Motor Driven, Rotary Pump, Expanding Battery), Care Setting (Hospitals) – Global Forecast to 2026출판사 | MarketsandMarkets |
출판년월 | 2021년7월 |
폐이지수 | 194 |
도표수 | 165 |
구성 | 영문조사보고서 |
리포트목차 | 견적문의의뢰 |
목차
1 INTRODUCTION 18 1.1 OBJECTIVES OF THE STUDY 18 1.2 MARKET DEFINITION 18 1.2.1 INCLUSIONS AND EXCLUSIONS 18 1.3 MARKET SCOPE 19 1.3.1 MARKETS COVERED 19 FIGURE 1 WEARABLE INJECTORS MARKET SEGMENTATION 19 FIGURE 2 WEARABLE INJECTORS MARKET, BY REGION 19 1.3.2 YEARS CONSIDERED FOR THE STUDY 20 1.4 CURRENCY 20 TABLE 1 STANDARD CURRENCY CONVERSION RATES 20 1.5 LIMITATIONS 21 1.6 STAKEHOLDERS 21 1.7 SUMMARY OF CHANGES 21 2 RESEARCH METHODOLOGY 23 2.1 RESEARCH DATA 23 FIGURE 3 RESEARCH DESIGN 23 2.1.1 SECONDARY DATA 24 2.1.1.1 Key data from secondary sources 25 2.1.2 PRIMARY DATA 25 FIGURE 4 PRIMARY SOURCES 26 2.1.2.1 Key data from primary sources 27 2.1.2.2 Key industry insights 28 FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (WEARABLE INJECTORS MARKET) 28 FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 29 2.2 MARKET SIZE ESTIMATION 29 FIGURE 7 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 30 FIGURE 8 REVENUE SHARE ANALYSIS ILLUSTRATION: AMGEN INC. 30 FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: WEARABLE INJECTORS MARKET (2020) 31 FIGURE 10 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE WEARABLE INJECTORS MARKET (2021–2026) 32 FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 33 FIGURE 12 BOTTOM-UP APPROACH 34 FIGURE 13 TOP-DOWN APPROACH 34 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 34 FIGURE 14 DATA TRIANGULATION METHODOLOGY 35 2.4 MARKET RANKING ESTIMATION 36 2.5 ASSUMPTIONS FOR THE STUDY 36 2.6 RISK ASSESSMENT 37 2.7 COVID-19 HEALTH ASSESSMENT 37 2.8 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE WEARABLE INJECTORS MARKET 37 3 EXECUTIVE SUMMARY 38 FIGURE 15 WEARABLE INJECTORS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION) 38 FIGURE 16 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION) 39 FIGURE 17 WEARABLE INJECTORS MARKET, BY THERAPY, 2021 VS. 2026 (USD MILLION) 40 FIGURE 18 WEARABLE INJECTORS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION) 41 FIGURE 19 GEOGRAPHIC SNAPSHOT OF THE WEARABLE INJECTORS MARKET 42 4 PREMIUM INSIGHTS 43 4.1 WEARABLE INJECTORS MARKET OVERVIEW 43 FIGURE 20 SHIFT OF HEALTHCARE DELIVERY TOWARD HOMECARE DUE TO COVID-19 IS DRIVING MARKET GROWTH 43 4.2 NORTH AMERICAN WEARABLE INJECTORS MARKET, BY COUNTRY AND THERAPY 44 FIGURE 21 DIABETES SEGMENT COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN MARKET IN 2020 44 4.3 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 45 FIGURE 22 MARKET IN CHINA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 45 4.4 WEARABLE INJECTORS MARKET: REGIONAL MIX 46 FIGURE 23 NORTH AMERICA IS THE LARGEST MARKET FOR WEARABLE INJECTORS 46 5 MARKET OVERVIEW 47 5.1 INTRODUCTION 47 5.2 MARKET DYNAMICS 47 FIGURE 24 WEARABLE INJECTORS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 47 5.2.1 DRIVERS 48 5.2.1.1 Shift of healthcare delivery toward homecare due to COVID-19 48 5.2.1.2 Advantages of wearable injectors in the administration of various drugs 48 5.2.1.3 Growing prevalence of chronic diseases 49 5.2.1.4 Favorable reimbursement scenario in major markets 49 5.2.1.5 Technological advancements and design development 49 5.2.2 RESTRAINTS 50 5.2.2.1 Preference for alternative drug delivery modes 50 5.2.2.2 High cost of wearable injectors 50 5.2.3 OPPORTUNITIES 50 5.2.3.1 Increasing demand for biologics and mAbs 50 FIGURE 25 US: BIOLOGIC MEDICINES IN DEVELOPMENT, 2017 51 5.2.4 CHALLENGES 51 5.2.4.1 Unfavorable reimbursement structure in developing countries 51 6 INDUSTRY INSIGHTS 52 6.1 TECHNOLOGY ANALYSIS 52 6.2 PRICING ANALYSIS 52 TABLE 2 AVERAGE SELLING PRICE: WEARABLE INJECTORS 52 6.3 VALUE CHAIN ANALYSIS 53 FIGURE 26 WEARABLE INJECTORS MARKET: VALUE CHAIN ANALYSIS 53 6.4 ECOSYSTEM MARKET MAP 53 FIGURE 27 WEARABLE INJECTORS MARKET: ECOSYSTEM MARKET MAP 54 6.5 SUPPLY CHAIN ANALYSIS 54 FIGURE 28 WEARABLE INJECTORS MARKET: SUPPLY CHAIN ANALYSIS 55 6.6 PORTER’S FIVE FORCES ANALYSIS 56 FIGURE 29 PORTER’S FIVE FORCES ANALYSIS (2020): WEARABLE INJECTORS MARKET 56 TABLE 3 WEARABLE INJECTORS MARKET: PORTER’S FIVE FORCES ANALYSIS 56 6.6.1 THREAT OF NEW ENTRANTS 56 6.6.1.1 Growth in the overall wearable injectors market 57 6.6.1.2 Growing consolidation 57 6.6.1.3 Poor financing environment 57 6.6.2 THREAT OF SUBSTITUTES 57 6.6.3 BARGAINING POWER OF SUPPLIERS 58 6.6.4 BARGAINING POWER OF BUYERS 58 6.6.5 INTENSITY OF COMPETITIVE RIVALRY 59 6.7 REGULATORY ANALYSIS 59 6.8 PATENT ANALYSIS 60 6.8.1 PATENT PUBLICATION TRENDS FOR WEARABLE INJECTORS 60 FIGURE 30 GLOBAL PATENT PUBLICATION TRENDS (2015–2020) 60 6.9 IMPACT OF COVID-19 ON THE WEARABLE INJECTORS MARKET 61 7 WEARABLE INJECTORS MARKET, BY TYPE 62 7.1 INTRODUCTION 63 TABLE 4 WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 63 7.2 ON-BODY INJECTORS 63 7.2.1 ON-BODY INJECTORS SEGMENT DOMINATED THE MARKET IN 2020 63 TABLE 5 ON-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 64 7.3 OFF-BODY INJECTORS 64 7.3.1 OFF-BODY INJECTORS SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 64 TABLE 6 OFF-BODY WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 65 8 WEARABLE INJECTORS MARKET, BY TECHNOLOGY 66 8.1 INTRODUCTION 67 TABLE 7 WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 67 8.2 SPRING-BASED TECHNOLOGY 67 8.2.1 SPRING-BASED TECHNOLOGY ENABLES THE DELIVERY OF DRUGS WITH HIGHER VOLUME AND VISCOSITY 67 TABLE 8 WEARABLE INJECTORS MARKET FOR SPRING-BASED TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 68 8.3 MOTOR-DRIVEN TECHNOLOGY 68 8.3.1 THESE DEVICES CAN GENERATE HIGH FORCE FOR SUBCUTANEOUS INJECTIONS OF HIGH-VISCOSITY LIQUIDS 68 TABLE 9 WEARABLE INJECTORS MARKET FOR MOTOR-DRIVEN TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 69 8.4 ROTARY PUMP TECHNOLOGY 69 8.4.1 THESE DEVICES SHOW HIGH PRECISION AND THE POSSIBILITY TO NOT ALTER THE FLUID PROPERTIES 69 TABLE 10 WEARABLE INJECTORS MARKET FOR ROTARY PUMP TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 70 8.5 EXPANDING BATTERY TECHNOLOGY 70 8.5.1 EXPANDING BATTERY TECHNOLOGY SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 70 TABLE 11 WEARABLE INJECTORS MARKET FOR EXPANDING BATTERY TECHNOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 71 8.6 OTHER TECHNOLOGIES 71 TABLE 12 WEARABLE INJECTORS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2019–2026 (USD MILLION) 72 9 WEARABLE INJECTORS MARKET, BY THERAPY 73 9.1 INTRODUCTION 74 TABLE 13 WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 74 9.2 DIABETES 74 9.2.1 HIGH PREVALENCE OF DIABETES ACROSS THE GLOBE TO DRIVE THE GROWTH OF THIS MARKET SEGMENT 74 TABLE 14 INSULIN DEVICES AVAILABLE FOR DIABETES PATIENTS 75 TABLE 15 WEARABLE INJECTORS MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD MILLION) 76 9.3 IMMUNO-ONCOLOGY 76 9.3.1 IMMUNO-ONCOLOGY SEGMENT TO WITNESS NEGATIVE GROWTH DURING THE FORECAST PERIOD 76 TABLE 16 WEARABLE INJECTORS MARKET FOR IMMUNO-ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION) 77 9.4 CARDIOVASCULAR DISEASES 77 9.4.1 CARDIOVASCULAR DISEASES SEGMENT TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD 77 TABLE 17 WEARABLE INJECTORS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 78 9.5 OTHER THERAPIES 78 TABLE 18 WEARABLE INJECTORS MARKET FOR OTHER THERAPIES, BY COUNTRY, 2019–2026 (USD MILLION) 79 10 WEARABLE INJECTORS MARKET, BY END USER 80 10.1 INTRODUCTION 81 TABLE 19 WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 81 10.2 HOSPITALS AND CLINICS 81 10.2.1 HOSPITALS AND CLINICS ARE THE LARGEST END USERS OF WEARABLE INJECTORS 81 TABLE 20 WEARABLE INJECTORS MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY, 2019–2026 (USD MILLION) 82 10.3 HOME HEALTHCARE SETTINGS 82 10.3.1 HOME HEALTHCARE SETTINGS SEGMENT TO WITNESS HIGHER GROWTH DURING THE FORECAST PERIOD 82 TABLE 21 WEARABLE INJECTORS MARKET FOR HOME HEALTHCARE SETTINGS, BY COUNTRY, 2019–2026 (USD MILLION) 83 11 WEARABLE INJECTORS MARKET, BY REGION 84 11.1 INTRODUCTION 85 FIGURE 31 WEARABLE INJECTORS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 85 TABLE 22 WEARABLE INJECTORS MARKET, BY REGION, 2019–2026 (USD MILLION) 86 11.2 NORTH AMERICA 86 FIGURE 32 NORTH AMERICA: WEARABLE INJECTORS MARKET SNAPSHOT 87 TABLE 23 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 88 TABLE 24 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 88 TABLE 25 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 89 TABLE 26 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 89 TABLE 27 NORTH AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 90 11.2.1 US 90 11.2.1.1 Growing IV infusion expenditure is a key factor driving the US market. 90 TABLE 28 US: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 91 TABLE 29 US: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 91 TABLE 30 US: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 92 TABLE 31 US: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 92 11.2.2 CANADA 92 11.2.2.1 Rising prevalence of chronic diseases in Canada to drive the demand for drugs that can be self-administered 92 TABLE 32 CANADA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 93 TABLE 33 CANADA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 94 TABLE 34 CANADA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 94 TABLE 35 CANADA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 95 11.3 EUROPE 95 FIGURE 33 EUROPE: WEARABLE INJECTORS MARKET SNAPSHOT 96 TABLE 36 EUROPE: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 97 TABLE 37 EUROPE: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 97 TABLE 38 EUROPE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 98 TABLE 39 EUROPE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 98 TABLE 40 EUROPE: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 99 11.3.1 GERMANY 99 11.3.1.1 Availability of government support for drug development and approval to drive growth in the German wearable injectors market 99 TABLE 41 GERMANY: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 100 TABLE 42 GERMANY: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 100 TABLE 43 GERMANY: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 101 TABLE 44 GERMANY: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 101 11.3.2 UK 102 11.3.2.1 Government focus on biosimilar innovation to drive the market growth 102 TABLE 45 UK: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 102 TABLE 46 UK: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 103 TABLE 47 UK: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 103 TABLE 48 UK: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 104 11.3.3 FRANCE 104 11.3.3.1 100% coverage for diabetes by SHI to drive market growth in France 104 TABLE 49 FRANCE: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 104 TABLE 50 FRANCE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 105 TABLE 51 FRANCE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 105 TABLE 52 FRANCE: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 106 11.3.4 REST OF EUROPE 106 TABLE 53 ROE: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 107 TABLE 54 ROE: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 107 TABLE 55 ROE: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 108 TABLE 56 ROE: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 108 11.4 ASIA PACIFIC 108 TABLE 57 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 109 TABLE 58 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 109 TABLE 59 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 110 TABLE 60 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 110 TABLE 61 ASIA PACIFIC: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 111 11.4.1 JAPAN 111 11.4.1.1 Large number of patients suffering from diabetes, CVD, and other chronic conditions to drive market growth in Japan 111 TABLE 62 JAPAN: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 112 TABLE 63 JAPAN: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 112 TABLE 64 JAPAN: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 113 TABLE 65 JAPAN: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 113 11.4.2 CHINA 113 11.4.2.1 Large diabetic population to drive market growth in China 113 TABLE 66 CHINA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 114 TABLE 67 CHINA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 114 TABLE 68 CHINA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 115 TABLE 69 CHINA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 115 11.4.3 INDIA 116 11.4.3.1 Large diabetic population to drive the market for wearable injectors in India 116 TABLE 70 INDIA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 116 TABLE 71 INDIA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 117 TABLE 72 INDIA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 117 TABLE 73 INDIA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 118 11.4.4 REST OF ASIA PACIFIC 118 TABLE 74 ROAPAC: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 118 TABLE 75 ROAPAC: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 119 TABLE 76 ROAPAC: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 119 TABLE 77 ROAPAC: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 120 11.5 LATIN AMERICA 120 11.5.1 INCREASING PREVALENCE OF DIABETES AND OTHER CHRONIC CONDITIONS TO DRIVE THE MARKET IN LATIN AMERICA 120 TABLE 78 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 120 TABLE 79 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 121 TABLE 80 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 121 TABLE 81 LATIN AMERICA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 122 11.6 MIDDLE EAST & AFRICA 122 11.6.1 DEMAND FOR WEARABLE INJECTORS IN THE MANAGEMENT OF DIABETES AND CVD IS EXPECTED TO INCREASE IN THE MIDDLE EAST AND AFRICA 122 TABLE 82 CONFERENCES IN THE MIDDLE EAST AND AFRICA (2016–2018) 122 TABLE 83 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY TYPE, 2019–2026 (USD MILLION) 123 TABLE 84 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION) 123 TABLE 85 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY THERAPY, 2019–2026 (USD MILLION) 124 TABLE 86 MIDDLE EAST AND AFRICA: WEARABLE INJECTORS MARKET, BY END USER, 2019–2026 (USD MILLION) 124 12 COMPETITIVE LANDSCAPE 125 12.1 INTRODUCTION 125 FIGURE 34 KEY MARKET DEVELOPMENTS (JANUARY 2018 TO JULY 2021) 126 12.2 REVENUE ANALYSIS OF KEY MARKET PLAYERS 127 FIGURE 35 REVENUE ANALYSIS OF THE KEY PLAYERS OPERATING IN THE WEARABLE INJECTORS MARKET 127 12.3 MARKET SHARE ANALYSIS 127 FIGURE 36 WEARABLE INJECTORS MARKET SHARE, BY KEY PLAYER, 2020 128 12.4 COMPETITIVE SCENARIO 129 12.4.1 PRODUCT LAUNCHES 129 TABLE 87 WEARABLE INJECTORS MARKET: PRODUCT LAUNCHES (JANUARY 2018 TO JULY 2021) 129 12.4.2 DEALS 129 TABLE 88 WEARABLE INJECTORS MARKET: DEALS (JANUARY 2018 TO JULY 2021) 129 12.4.3 OTHER DEVELOPMENTS 130 TABLE 89 WEARABLE INJECTORS MARKET: OTHER DEVELOPMENTS (JANUARY 2018 TO JULY 2021) 130 12.5 COMPETITIVE BENCHMARKING 131 12.6 COMPANY EVALUATION MATRIX 136 12.6.1 STARS 136 12.6.2 EMERGING LEADERS 136 12.6.3 PERVASIVE PLAYERS 136 12.6.4 EMERGING COMPANIES 136 FIGURE 37 WEARABLE INJECTORS MARKET: GLOBAL COMPANY EVALUATION MATRIX 137 12.7 COMPETITIVE LEADERSHIP MAPPING (SMES/START-UPS) 138 12.7.1 PROGRESSIVE COMPANIES 138 12.7.2 STARTING BLOCKS 138 12.7.3 RESPONSIVE COMPANIES 138 12.7.4 DYNAMIC COMPANIES 138 FIGURE 38 WEARABLE INJECTORS MARKET: COMPANY EVALUATION MATRIX FOR SMES/START-UPS 139 13 COMPANY PROFILES 140 13.1 KEY PLAYERS 140 (Business Overview, Products, Key Insights, Recent Developments, MnM View)* 13.1.1 AMGEN INC. 140 TABLE 90 AMGEN INC.: BUSINESS OVERVIEW 140 FIGURE 39 AMGEN INC.: COMPANY SNAPSHOT (2020) 141 13.1.2 MEDTRONIC PLC 144 TABLE 91 MEDTRONIC PLC: BUSINESS OVERVIEW 144 FIGURE 40 MEDTRONIC PLC: COMPANY SNAPSHOT (2020) 145 13.1.3 INSULET CORPORATION 147 TABLE 92 INSULET CORPORATION: BUSINESS OVERVIEW 147 FIGURE 41 INSULET CORPORATION: COMPANY SNAPSHOT (2020) 148 13.1.4 BECTON, DICKINSON AND COMPANY 151 TABLE 93 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 151 FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 152 13.1.5 YPSOMED 154 TABLE 94 YPSOMED: BUSINESS OVERVIEW 154 FIGURE 43 YPSOMED: COMPANY SNAPSHOT (2020) 154 13.1.6 UNITED THERAPEUTICS CORPORATION 157 TABLE 95 UNITED THERAPEUTICS CORPORATION: BUSINESS OVERVIEW 157 FIGURE 44 UNITED THERAPEUTICS CORPORATION: COMPANY SNAPSHOT (2020) 158 13.1.7 SUBCUJECT 160 TABLE 96 SUBCUJECT: BUSINESS OVERVIEW 160 13.1.8 ENABLE INJECTIONS 161 TABLE 97 ENABLE INJECTIONS: BUSINESS OVERVIEW 161 13.1.9 CEQUR SA 163 TABLE 98 CEQUR SA: BUSINESS OVERVIEW 163 13.1.10 SENSILE MEDICAL (A PART OF GERRESHEIMER) 164 TABLE 99 SENSILE MEDICAL: BUSINESS OVERVIEW 164 13.2 OTHER PLAYERS 165 13.2.1 STEADYMED THERAPEUTICS 165 TABLE 100 STEADYMED THERAPEUTICS: BUSINESS OVERVIEW 165 13.2.2 ATS AUTOMATION 166 TABLE 101 ATS AUTOMATION: BUSINESS OVERVIEW 166 FIGURE 45 ATS AUTOMATION: COMPANY SNAPSHOT (2020) 166 13.2.3 WEST PHARMACEUTICAL SERVICES, INC. 168 TABLE 102 WEST PHARMACEUTICAL SERVICES, INC.: BUSINESS OVERVIEW 168 FIGURE 46 WEST PHARMACEUTICAL SERVICES, INC.: COMPANY SNAPSHOT (2020) 168 13.2.4 UNILIFE CORPORATION 170 TABLE 103 UNILIFE CORPORATION: BUSINESS OVERVIEW 170 13.2.5 TANDEM DIABETES CARE 171 TABLE 104 TANDEM DIABETES CARE: BUSINESS OVERVIEW 171 FIGURE 47 TANDEM DIABETES CARE: COMPANY SNAPSHOT (2020) 171 13.2.6 VALERITAS, INC. 173 TABLE 105 VALERITAS, INC.: BUSINESS OVERVIEW 173 FIGURE 48 VALERITAS, INC.: COMPANY SNAPSHOT (2020) 173 13.2.7 BÜHLER MOTOR GMBH 175 TABLE 106 BÜHLER MOTOR GMBH: BUSINESS OVERVIEW 175 FIGURE 49 BÜHLER MOTOR GMBH: COMPANY SNAPSHOT (2020) 175 13.2.8 SONCEBOZ 177 TABLE 107 SONCEBOZ: BUSINESS OVERVIEW 177 13.2.9 NOBLE INTERNATIONAL LLC (AN APTAR PHARMA COMPANY) 178 TABLE 108 NOBLE INTERNATIONAL LLC: BUSINESS OVERVIEW 178 FIGURE 50 NOBLE INTERNATIONAL LLC: COMPANY SNAPSHOT (2020) 178 13.2.10 ELCAM DRUG DELIVERY DEVICES (E3D) 180 TABLE 109 ELCAM DRUG DELIVERY DEVICES: BUSINESS OVERVIEW 180 13.2.11 BESPAK EUROPE LTD. 181 TABLE 110 BESPAK EUROPE LTD.: BUSINESS OVERVIEW 181 FIGURE 51 BESPAK EUROPE LTD.: COMPANY SNAPSHOT (2020) 181 13.2.12 STEVANATO GROUP 183 TABLE 111 STEVANATO GROUP: BUSINESS OVERVIEW 183 13.2.13 SORREL MEDICAL 184 TABLE 112 SORREL MEDICAL: BUSINESS OVERVIEW 184 13.2.14 WEIBEL CDS 185 TABLE 113 WEIBEL CDS: BUSINESS OVERVIEW 185 13.2.15 NEUMA LLC 186 TABLE 114 NEUMA: BUSINESS OVERVIEW 186 *Details on Business Overview, Products, Key Insights, Recent Developments, MnM View might not be captured in case of unlisted companies. 14 APPENDIX 187 14.1 DISCUSSION GUIDE 187 14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 190 14.3 AVAILABLE CUSTOMIZATIONS 192 14.4 RELATED REPORTS 192 14.5 AUTHOR DETAILS 193
お問合せフォーム